E
83.94
-0.43 (-0.51%)
| Previous Close | 84.37 |
| Open | 83.52 |
| Volume | 1,234,151 |
| Avg. Volume (3M) | 5,108,354 |
| Market Cap | 48,332,652,544 |
| Price / Earnings (TTM) | 45.37 |
| Price / Earnings (Forward) | 28.49 |
| Price / Sales | 7.94 |
| Price / Book | 4.78 |
| 52 Weeks Range | |
| Earnings Date | 23 Jul 2026 |
| Profit Margin | 75.71% |
| Operating Margin (TTM) | 29.01% |
| Diluted EPS (TTM) | 2.42 |
| Quarterly Revenue Growth (YOY) | 6.20% |
| Quarterly Earnings Growth (YOY) | 1.70% |
| Total Debt/Equity (MRQ) | 6.86% |
| Current Ratio (MRQ) | 4.45 |
| Operating Cash Flow (TTM) | 876.20 M |
| Levered Free Cash Flow (TTM) | 1.45 B |
| Return on Assets (TTM) | 8.42% |
| Return on Equity (TTM) | 16.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Mixed |
| Medical Devices (Global) | Mixed | Mixed | |
| Stock | Edwards Lifesciences Corporatio | Mixed | Bullish |
AIStockmoo Score
0.8
| Analyst Consensus | NA |
| Insider Activity | 2.0 |
| Price Volatility | -1.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | 0.75 |
|
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Mid Growth |
| % Held by Insiders | 0.91% |
| % Held by Institutions | 89.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank, Frankfurt | 31 Mar 2026 | 12,811,902 |
No data within this time range.
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| BRULS ANNETTE | - | 92.21 | -109 | -10,051 |
| LIPPIS DANIEL J. | - | 92.21 | -619 | -57,078 |
| MISTRAS THEODORA | 91.33 | - | 99,920 | 9,125,694 |
| Aggregate Net Quantity | 99,192 | |||
| Aggregate Net Value ($) | 9,058,565 | |||
| Aggregate Avg. Buy ($) | 91.33 | |||
| Aggregate Avg. Sell ($) | 92.21 | |||
| Insider Range ($) | ||||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| BRULS ANNETTE | Officer | 11 Jul 2026 | Disposed (-) | 109 | 92.21 | 10,051 |
| LIPPIS DANIEL J. | Officer | 10 Jul 2026 | Automatic sell (-) | 619 | 92.21 | 57,078 |
| LIPPIS DANIEL J. | Officer | 10 Jul 2026 | Option execute | 619 | - | - |
| MISTRAS THEODORA | Officer | 09 Jul 2026 | Acquired (+) | 99,920 | 91.33 | 9,125,694 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |